Table 2.

Univariate analysis for overall survival (OS)

Characteristics	Patient Number (n = 216) (%)	Median OS Hazard ratio†	95% CI	P-value
Age, (years)
Age <35	25 (11.6)	1		0.898
Age ≥35	191 (88.4)	1.063	0.419–2.696
Performance status
ECOG 0–1	213 (98.6)	1		0.048
ECOG 2	3 (1.4)	3.754	0.904–12.588
Pathologic characteristics
Invasive ductal carcinoma	206 (95.4)	1		0.008
Others*	10 (4.6)	3.684	1.312–10.341
Initial clinical stage
Operable (IIA, IIB, IIIA)	155 (71.8)	1		0.030
Inoperable (IIIB, IIIC)	61 (28.2)	2.283	1.074–4.242
Receptor status
ER
Positive	99 (45.8)	1		0.049
Negative	117 (54.2)	2.081	0.996–3.189
PR
Positive	73 (33.8)	1		0.258
Negative	143 (66.2)	1.542	0.754–2.832
HER2
Positive	67 (31.0)	1		0.730
Negative	149 (69.0)	1.117	0.697–2.177
Triple negative phenotype
Non triple negative	148 (68.5)	1		0.033
Triple negative	68 (31.5)	1.995	1.004–3.447
ABCB1 C3435T
CC + CT	185 (85.6)	1		0.024
TT	31 (14.4)	0.223	0.054–0.972
ABCB1 G2677T/A
GG	38 (17.6)	1		0.566
Non-GG	178 (82.4)	1.168	0.543–2.510
ABCB1 C1236T
CC + CT	136 (63.0)	1		0.126
TT	80 (37.0)	0.688	0.335–1.256
Type of surgery
Breast conserving	87 (40.3)	1		0.036
Mastectomy	129 (59.7)	2.083	1.074–4.022
Menopausal status
Pre-menopause	146 (67.6)	1		0.244
Post-menopause	70 (32.4)	1.323	0.724–2.419

ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor; PR, progesterone receptor.

^†Hazard ratio was calculated by Cox's proportional hazard model. If the hazard ratio is >1, the hazard ratio can be thought of as the average increased risk of death compared with the reference group (upper line).

^*Among the 10 patients, 7 had invasive lobular carcinomas, 3 medullary carcinomas and 1 tubular carcinoma.